Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer

Breast

Volumn 22, Issue S2, 2013, Pages

  Abu Khalf, Maysa ^a   Pusztai, Lajos ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Clinical utility; Cost effectiveness; Gene signatures; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GENOMICS; HEALTH CARE UTILIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRE INVASIVE BREAST CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; TREND STUDY; TUMOR INVASION;

CLINICAL UTILITY; COST-EFFECTIVENESS; GENE SIGNATURES; PROGNOSTIC FACTORS;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; FORECASTING; GENETIC TESTING; GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884723617     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.015     Document Type: Article

References (39)

1. Bast R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. JClin Oncol 2001, 19:1865-1878.
2. Molina R., Barak V., van Dalen A., et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol 2005, 26:281-293.
3. van de Vijver M.J., He Y.D., van't Veer L.J., et al. Agene-expression signature as a predictor of survival in breast cancer. NEngl J Med 2002, 347:1999-2009.
4. Wang Y., Klijn J.G., Zhang Y., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
5. Sotiriou C., Wirapati P., Loi S., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. JNatl Cancer Inst 2006, 98:262-272.
6. Paik S., Shak S., Tang G., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351:2817-2826.
7. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JClin Oncol 2006, 24:3726-3734.
8. Parker J.S., Mullins M., Cheang M.C., Leung S., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009, 27:1160-1167.
9. Bartlett J.M.S., Bloom K.J., Piper T., et al. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter pathology study. JClin Oncol 2012, 30:4477-4484.
10. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005, 2:416-422.
11. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. JNatl Cancer Inst 2009, 101:1446-1452.
12. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25:5287-5312.
13. National Comprehensive Cancer Network clinical practice guidelines in oncology breast cancer v. 1 2009, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
14. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
15. Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10(4):R65.
16. Popovici V., Chen W., Gallas B.G., Hatzis C., et al. Effect of training sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res 2010, 12(1):R5. 10.1186/bcr2468.
17. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28(8):827-838. MAQC Consortium.
18. Rody A., Karn T., Liedtke C., Pusztai L., et al. Aclinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011, 13(5):R97.
19. Hatzis C., Pusztai L., Valero V., Booser D.J., et al. Agenomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAm Med Assoc 2011, 305(18):1873-1881.
20. Karn T., Pusztai L., Holtrich U., Iwamoto T., et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One 2011, 6(12):e28403.
21. Sotiriou C., Pusztai L. Gene expression signatures in breast cancer. NEngl J Med 2009, 360(8):790-800.
22. Hassett M.J., Silver S.M., Hughes M.E., et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. JClin Oncol 2012, 30:2218-2222.
23. Kelly C.M., Krishnamurthy S., Bianchini G., et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010, 116:5161-5167.
24. Oratz R., Paul D., Cohn A.L., et al. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. JOncol Pract 2007, 3:182-186.
25. Asad J., Jacobson A.F., Estabrook A., et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am J Surg 2008, 196:527-529.
26. Hall P.S., McCabe C., Stein R.C., Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. JNatl Cancer Inst 2012, 104:56-66.
27. Lyman G.H., Cosler L.E., Kuderer N.M., et al. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 2007, 109:1011-1018.
28. Hornberger J., Cosler L.E., Lyman G.H. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 2005, 11:313-324.
29. Kondo M., Hoshi S., Ishiguro H., Yoshibayashi H., Toi M. Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 2008, 112:175-187.
30. Tsoi D.T., Inoue M., Kelly C.M., Verma S., Pritchard K.I. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. Oncologist 2010, 15:457-465.
31. Iwamoto T., Lee J.S., Bianchini G., Hubbard R.E., et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011, 130:155-164.
32. Azim H.A., Michiels S., Zagouri F., Delaloge S., et al. Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013, 24:647-654.
33. ®) and the PAM50 breast cancer intrinsic classifier in early stage ER-positive breast cancer. Oncologist 2012, 17:492-498.
34. Cuzick J., Dowsett M., Pineda S., et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. JClin Oncol 2012, 29:4273-4278.
35. Dowset M., Nielsen T.O., Hern R.A., et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. JNatl Cancer Inst 2011, 103:1-9.
36. Desmedt C., Piette F., Loi S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transBIG independent validation series. Clin Cancer Res 2007, 13:3207-3214.
37. Sgroi D., Siesta I., Zhang Y., et al. Comparative performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in HR-positive, LN-negative breast cancer patients: a TransATAC study. Cancer Res 2012, 72(Suppl.24). 103s S1-9.
38. Bianchini G., Pusztai L., Iwamoto T., Kelly C.M., et al. Molecular tumor characteristics influence adjuvant endocrine treatment outcome. Cancer Res 2011, 71(Suppl.24). 98s (#S1-7).
39. Dubsky P., Brase J.C., Fisch K., et al. The EndoPredict score identifies late distant metastasis in Er+/HER2- breast cancer patients. Cancer Res 2012, 72(Suppl.24). 103s S4-3.